Printer Friendly

Neoplasm rate argues for early colonoscopies.

SAN ANTONIO -- Patients with primary sclerosing cholangitis and inflammatory bowel disease were as likely to develop colon cancer within 2 years of diagnosis as they were within 8-10 years of diagnosis, based on data from 54 patients.

Yearly colonoscopies are often recommended for patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), but the evidence to support early screening has been limited, said Dr. Erin Thackeray of the Mayo Clinic in Rochester, Minn.

In this study, the researchers reviewed medical charts from 54 adults with. PSC and IBD who were seen at the Mayo Clinic between 1995 and 2005 and were later diagnosed with colonic neoplasms. Average age at the time of colon cancer diagnosis was 51 years, and 70% of the patients were male.

The occurrence of colonic neoplasms per 100 patient-years of follow-up was 21.5 within 2 years, 20.5 at 2-4 years, 19.3 at 4-6 years, 16.8 at 6-8 years, and 20.4 at 8-10 years. Fourteen patients had colon cancer: two in the cecum, five in the ascending colon, four in the transverse colon, and three in the rectosigmoid colon.

The study was limited by its small size, but the results "support early and aggressive screening for colon cancer" in this patient population, said Dr. Thackeray, who noted she had no financial conflicts to disclose.

FROM THE ANNUAL MEETING OF THE AMERICAN COLLEGE OF GASTROENTEROLOGY

COPYRIGHT 2010 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:GASTROENTEROLOGY
Author:Splete, Heidi
Publication:Internal Medicine News
Article Type:Brief article
Geographic Code:1USA
Date:Dec 1, 2010
Words:234
Previous Article:Statin use tied to 10% cut in colorectal Ca risk.
Next Article:Lower BMI criterion for obesity surgery backed.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters